Phase 4 Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 55 years, both male and female
- People whose migraines first started before the age of 50
- People who have been diagnosed with migraine (according to an international medical standard called ICHD-3) for at least one year
- People who have had between 2 and 8 migraine attacks per month
- People who have been on stable migraine prevention medication, if taking any, for at least 2 months before the trial starts and plan to stay on the same dose throughout the study
- Women who could become pregnant must be using effective contraception during the study
- People who are able to give written consent and are willing and able to follow the study schedule
Who may not be able to join:
- People diagnosed with other types of headache disorders, such as cluster headaches or tension headaches
- People with a history of chronic migraine (very frequent, ongoing migraine)
- People whose migraines have not responded to multiple standard treatments, based on European Headache Federation guidelines
- People who have taken any migraine-relief medication within 48 hours before using the study product
- People with a history of psychiatric or neurological conditions (other than migraine), or other medical conditions that could affect the study results
- People with a known sensitivity or allergy to menthol, lavender, rosemary, eucalyptus, wintergreen, or basil oil
- People who have any skin lesions in the areas where the study product would be applied
- People who have taken part in another clinical trial within 30 days before screening
- People with a history of substance use disorders
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study
- People who have taken certain specific medications within 14 days before the study, including carbamazepine, cilostazol, citalopram, clarithromycin, clobazam, colchicine, cyclosporine, digoxin, itraconazole, phenobarbital, phenytoin, rifampin, sirolimus, tacrolimus, tizanidine, or warfarin (confirm with trial site if unsure about any medications)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +982143473000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The percentage of participants who report improvement in headache pain by at least one severity level (according to the 4-point scale) at 2 hours after treatment, and before the use of any rescue medication.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.